VIDEO: SGLT2 inhibitors may protect organs in acute illness
Click Here to Manage Email Alerts
In this video exclusive, Richard E. Pratley, MD, talks with Mikhail Kosiborod, MD, FACC, FAHA, about the DARE-19 trial, which explored repurposing existing medications to treat COVID-19.
Pratley is the Samuel E. Crockett Chair in Diabetes Research and medical director of AdventHealth Diabetes Institute, and Kosiborod is vice president for research and the Ben McCallister, MD, Endowed Chair in Cardiovascular Research at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine.
The rationale behind studying SGLT2 inhibitors for COVID-19 treatment lay in their mechanism of action and data from clinical trials that this drug class can provide organ protection in patients under stable conditions. DARE-19 extended the investigation to similar patients under more acute circumstances, such as COVID-19, Kosiborod said.
Pratley and Kosiborod discuss the quickly changing event rate during the COVID-19 pandemic, the hypothesis that SGLT2 can provide organ protection in acute illness beyond COVID-19, and the current practice of discontinuing SGLT2 inhibitors in the hospital.
Collapse
Read more about
Click Here to Manage Email Alerts